Sava raises $36M Series B and signs European deal with Ascensia for its next-generation glucose microsensor

Sava is building the foundation for preventative health by unlocking a new dimension in health monitoring. Its platform enables real-time sensing of molecules under the skin - starting with a next-generation glucose microsensor. Sava raises $36M Series B led by Ascensia Diabetes Care, a member of PHC Group, with strong participation from institutional investors Balderton Capital, Norrsken VC, Simplyhealth Ventures, JamJar Investments, Pentland Ventures, and many more.